U.S. market Closed. Opens in 13 hours 33 minutes

KYTX | Kyverna Therapeutics, Inc. Common Stock Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-31
RevenueN/A7.03M5.66M
Cost of Revenue1.71M1.05M586.00K
Gross Profit-1.71M5.97M5.07M
Operating Expenses62.41M36.41M32.00M
Selling, General & Admin12.48M8.01M6.15M
Research & Development49.92M28.40M25.85M
Other Operating ExpensesN/A-9.00K-2.00K
Operating Income-62.41M-29.38M-26.35M
Other Expenses / Income2.04M491.00K-4.00K
Before Tax Income-60.37M-28.89M-26.35M
Income Tax ExpensesN/A56.00K1.00K
Net Income-60.37M-28.89M-26.35M
Interest Expenses187.00K65.00K3.00K
Basic Shares Outstanding673.62M25.80M25.80M
Diluted Shares Outstanding673.62M25.80M25.80M
EBITDA-58.47M-27.78M-25.76M
EBITDA Margin0.00%-395.40%-455.46%
EBIT-60.18M-28.77M-26.35M
EBIT Margin0.00%-409.57%-465.81%
Financial Year End2023-12-312022-12-312021-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙